Literature DB >> 8943285

Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels.

T F Orntoft1, E M Vestergaard, E Holmes, J S Jakobsen, N Grunnet, M Mortensen, P Johnson, P Bross, N Gregersen, K Skorstengaard, U B Jensen, L Bolund, H Wolf.   

Abstract

Fucosylated glycoproteins carrying alpha1-4 fucose residues are of importance for cell adhesion and as tumor markers. The Lewis gene, FUT3, encodes the only known alpha1-4-fucosyltransferase (FucT), and individuals who are deficient in this enzyme type as Lewis-negative on erythrocytes. We examined the mutational spectrum of the Lewis gene in Denmark and found 6 different mutations. Five, T59G, T202C, C314T, G508A, and T1067A, were frequent, and one, C445A, was only detected in one out of 40 individuals. Allele-specific polymerase chain reaction as well as cloning of FUT3 alleles showed that the 202 and 314 mutations were co-located on the same allele. COS7 cells transfected with an allele having the 202/314 mutations lacked enzyme activity. Polymerase chain reaction-cleavage assays were established for the genotyping of healthy individuals as well as 20 genuine Lewis-negative cancer patients and 10 non-genuine. The latter have Lewis-negative erythrocytes but saliva alpha1-4FucT activity. The genuine Lewis-negative individuals had mutations on both FUT3 alleles. In 66 healthy individuals, a gene dosage effect was detected as FUT3 heterozygous individuals had a lower alpha1-4FucT activity in saliva than did homozygous wild-type individuals. The lower enzyme level in heterozygous individuals resulted in a significantly (p < 0.04) lower level of circulating sialyl-Lewis a structure in serum. This has the clinical impact that cut-off levels in tumor marker assays should be defined on the basis of genotyping. In the group of non-genuine Lewis-negative cancer patients, whose erythrocytes convert from Lewis-positive to Lewis-negative during the disease, FUT3 heterozygosity was significantly (p < 0.05) more common.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943285     DOI: 10.1074/jbc.271.50.32260

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  The aberrant expression of Lewis a antigen in intestinal metaplastic cells of gastric mucosa is caused by augmentation of Lewis enzyme expression.

Authors:  Y Ikehara; S Nishihara; T Kudo; T Hiraga; K Morozumi; T Hattori; H Narimatsu
Journal:  Glycoconj J       Date:  1998-08       Impact factor: 2.916

2.  Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.

Authors:  Katie Partyka; Kevin A Maupin; Randall E Brand; Brian B Haab
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

3.  Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.

Authors:  Matthew C Dallos; Andrew B Eisenberger; Susan E Bates
Journal:  Oncologist       Date:  2019-10-01

4.  Fucosyltransferase 3 polymorphism and atherothrombotic disease in the Framingham Offspring Study.

Authors:  Luc Djoussé; Samer Karamohamed; Alan G Herbert; Ralph B D'Agostino; L Adrienne Cupples; R Curtis Ellison
Journal:  Am Heart J       Date:  2007-04       Impact factor: 4.749

Review 5.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population.

Authors:  Jacinta Serpa; Raquel Almeida; Carla Oliveira; Filipe Santos Silva; Elisabete Silva; Celso Reis; Jacques Le Pendu; Graça Oliveira; Luís Manuel Cunha Ribeiro; Leonor David
Journal:  J Hum Genet       Date:  2003-03-20       Impact factor: 3.172

7.  CA 19-9 and pancreatic cancer.

Authors:  Erxi Wu; Shuang Zhou; Kruttika Bhat; Qingyong Ma
Journal:  Clin Adv Hematol Oncol       Date:  2013-01

8.  Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Authors:  Lipika Goyal; Aparna Govindan; Rahul A Sheth; Valentina Nardi; Lawrence S Blaszkowsky; Jason E Faris; Jeffrey W Clark; David P Ryan; Eunice L Kwak; Jill N Allen; Janet E Murphy; Supriya K Saha; Theodore S Hong; Jennifer Y Wo; Cristina R Ferrone; Kenneth K Tanabe; Dawn Q Chong; Vikram Deshpande; Darrell R Borger; A John Iafrate; Nabeel Bardeesy; Hui Zheng; Andrew X Zhu
Journal:  Oncologist       Date:  2015-08-05

Review 9.  Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.

Authors:  Matthew C Dallos; Andrew B Eisenberger; Susan E Bates
Journal:  Oncologist       Date:  2019-10-01

10.  Factors associated with serum CA19-9 levels among healthy children: a cross-sectional study.

Authors:  Sayo Kawai; Nobuyuki Hamajima; Sueli M Oba-Shinjo; Lucy S Ito; Miyuki Uno; Suely K N Marie
Journal:  BMC Clin Pathol       Date:  2012-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.